Gastric Cancer Diagnostic Procedure Market Size Forecasts at 6.5% CAGR during (2022-2028) – Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized | The Insight Partners

The global gastric cancer diagnostic procedure market size is growing from USD 1.30 billion in 2022 to USD 1.91 billion by 2028; it is estimated to register a CAGR of 6.5% from 2022 to 2028.

New York, March 02, 2023 (GLOBE NEWSWIRE) — According to The Insight Partners, “Gastric Cancer Diagnostic Procedure Market Size, Share, Growth, Trends and Global Forecasts to 2028 – COVID-19 Impact and Global Analysis By Healthcare Provider (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Symptom Type (Symptomatic and Asymptomatic), Body Fluid (Blood, Urine, Saliva, Stomach Wash/Gastric Juice, Tissue, and Others), Procedure (Endoscopic Procedures, Biopsy & Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics & Immunoassays, and Others), Offering [Instruments, Reagents & Consumables (Including Kits), and Services], and Disease Indication (Early Gastric Cancer and Gastric Cancer Advanced Types)”, the global gastric cancer diagnostic procedure market growth is driven by rise in prevalence of gastrointestinal diseases, surging cases of helicobacter pylori infection and development of AI-Based gastric cancer diagnostic platform.

Download PDF Brochure at

Global Gastric Cancer Diagnostic Procedure Market – Report Scope:

Market Size Value in USD 1.30 Billion in 2022
Market Size Value by USD 1.91 Billion by 2028
Growth rate CAGR of 6.5% from 2022 to 2028
Forecast Period 2022-2028
Base Year 2022
No. of Pages 398
No. of Tables 408
No. of Charts & Figures 96
Historical data available Yes
Segments covered Healthcare Provider, Symptom Type, Body Fluid, Procedure, Offering, and Disease Indication

Global Gastric Cancer Diagnostic Procedure Market: Competitive Landscape and Key Developments

Black Forest Medical Group, Integra LifeSciences Holdings Corp, Hill Rom Holding Inc, Eschmann Technologies Ltd, BD, TeDan Surgical Innovations, Barrfab Industria Commerce Import and Export of Hospital Equipment Ltda, Herbert Thailand Co Ltd, Medifa GmbH & Co KG, Micromar Industria e Com Ltda, and Schaerer Medical AG are a few of the key companies operating in the global gastric cancer diagnostic procedure market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name.

The product developments in the global gastric cancer diagnostic procedure market are mentioned below:

In October 2021, Agilent Technologies Inc. received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx, which is meant to provide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

In August 2021, MiRXES launched GASTROClear is the world’s first RNA-powered blood test for the early detection of gastric cancer. The kit assesses the quantities of 12 microRNA biomarkers, allowing the company to detect as much as 87% of all gastric cancers. These include those at stage 0 of gastric cancer, also known as high-grade dysplasia.

In August 2021, Myriad Genetics launched a new version of its MyRisk Hereditary Cancer Test. The test uses advanced technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with 8 hereditary cancer sites—breast, colon, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma cancers.

Inquiry Before Purchase:

Gastric cancer is a type of malignant cancer spread on the stomach’s inner lining. Age, diet, and stomach diseases are among the major risk factors for gastric cancer. Symptoms of gastric cancer include indigestion, heartburn, bloating, and stomach discomfort or pain. The presence of a huge patient population with gastrointestinal tumors, lymphoma, and adenocarcinoma; an increase in the geriatric population; and a rise in alcohol consumption and smoking are among the other factors contributing to the gastric cancer prevalence, thereby contributing to the gastric cancer diagnostic procedure market.

The US is currently leading the gastric cancer diagnostic procedure market, and the market growth in this country can be attributed to the growing prevalence of gastrointestinal diseases. For instance, the American Cancer Society estimated that ~26,500 new cases of gastric cancer (15,930 in men and 10,570 in women) would be diagnosed in 2023, and ~11,130 deaths (6,690 men and 4,440 women) would be due to gastric cancer. Further, the growing awareness of gastrointestinal diseases is likely to create growth opportunities for the market players in this country. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) is a nonprofit education and research organization that focuses on enhancing the quality of life for patients suffering from chronic digestive conditions. The 23rd Annual GERD Awareness Week was conducted from the 20th to the 26th in November 2022 with an aim to improve care by enhancing awareness and educating individuals.

Speak to Research Expert:

Surging Cases of Helicobacter Pylori Infection Boosts Global Gastric Cancer Diagnostic Procedure Market Growth:

Various studies in the past have established a relation between the colonization of the stomach with Helicobacter pylori (H. pylori), and the development of gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. According to a study “Current and Future Treatment of Helicobacter pylori Infections” in 2020, H. pylori is considered to be the most common human pathogens and was estimated to infect ~50% of the world’s population. The infection usually develops during infancy but remains asymptomatic, while long-standing clinical symptoms such as gastritis, peptic ulcer disease, and stomach cancer may be evident in the later stages of life. According to the Journal of Drug Assessment, more than 50% of the world’s population is infected with H. pylori. The World Health Organization (WHO) states that developing countries have a ~90% prevalence rate of H. pylori, whereas developed countries record a lower rate, i.e., ~50%. Moreover, the rate significantly higher in adults than in children, i.e., 48.6% and 32.6%, respectively.

Buy Premium Copy of Gastric Cancer Diagnostic Procedure Market Growth Report (2022-2028) at:

Browse other research published by The Insight Partners:

Global Gastric Balloon Market Size to 2027 – Global Analysis and Forecasts By Product (Single Gastric Balloons, Dual Gastric Balloons and Triple Gastric Balloons), Filling Material (Saline Filled and Gas Filled), End User (Bariatric Surgeons, Gastrointestinal Endoscopists, Nutritionists, Aesthetic Practitioners, and Other End Users), and Geography

Global Gastric Buttons Market Size Forecast to 2028 – COVID-19 Impact and Global Analysis by Offerings (Products and Accessories), Application (Children and Adults), Usage (Enteral Nutrition, Medications, Fluids, and Others), and End User (Hospitals, Clinics, and Others)

Global Gastric Bands Market Size Forecast to 2028 – Covid-19 Impact and Global Analysis – By Type (Adjustable Gastric Bands and Non-Adjustable Gastric Bands); End User (Hospitals , Ambulatory Surgical Centers, and Others) and Geography

Global Gastric Antisecretory Drug Market Size Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (H2-receptor Antagonists, Gastric Proton Pump Inhibitors, Others); Application (Dyspepsia, Peptic Ulcer, Gastroesophageal Reflux, Others); End-user (Hospitals, Clinics, Others) and Geography

Global Cancer Vaccines Market Size Forecast to 2027 – COVID-19 Impact and Global Analysis by Technology (Dendritic Cells Cancer Vaccines, Recombinant Cancer Vaccines, Antigen Cancer Vaccines, Whole Cell Cancer Vaccines and Viral Vector Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer and Other Indications), End User (Pediatrics and Adults) and Geography

Global Skin Cancer Market Size Forecast to 2028 – COVID-19 Impact and Global Analysis By Cancer Type (Melanoma, Non-melanoma); Type (Diagnosis , Therapeutics), and geography

Global Precision Cancer Imaging Market Size Forecast to 2028 – Covid-19 Impact and Global Analysis – By Type (Bipolar EleMagnetic Resonance Imagingctrosurgical Devices, Nuclear Imaging, Ultrasound Imaging); End User (Hospitals, Diagnostic Centers, Research Centers, Others)

Global Cancer Cachexia Market Size Forecast to 2028 – Covid-19 Impact and Global Analysis – By Therapeutics (Progestogens, Corticosteroids, Combination Therapies, Others); Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers, Others); Distribution Channel (Hospital Stores, Retail Pharmacy Store, Online Pharmacy) and Geography

Global Nanotechnology In Cancer Treatment Market Size Forecast to 2028 – COVID-19 Impact and Global Analysis By Application (Cancer Detection, Imaging, Drug Delivery, Radiotherapy, Immunotherapy, Phototherapy)

Global Breast Cancer Screening Market Size Forecast to 2027 – COVID-19 Impact and Global Analysis by Test Type (Blood Marker tests, Imaging Test, Genetic Test, Immunohistochemistry Test); End User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and Geography

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.